QIBA VOL-CT WebEx - July 14, 2008 Call Overview

In attendance:

Andrew Buckler, BSEE, MSCS (Moderator)  Kevin O’Donnell
Denise Aberle, MD  Nicholas Petrick, PhD
Rick Avila, MS  Sandra Scheib, RN, MSN, CNPWH
Charles Fenmore, PhD  Uri Shreter, PhD
Ronald Gottlieb, MD, MPH  Daniel Sullivan, MD
Frank Klein  Binsheng Zhao, PhD
Louis Marzella, MD, PhD  Linda Bresolin, PhD, MBA, CAE (RSNA)
P. David Mozley, MD  Tracy Schmidt, MS (RSNA)
James Mulshine, MD  Fiona Miller (RSNA)
Daniel Nicolson  Joe Koudelik (RSNA)

- Process - Integrate with the concept of IHE
  - Encourage improvement
  - Define profile
    - Vendors to conform to profile
    - Profile to stipulate (?)
    - Conformers, not “winners vs. loser” approach
      - Less competition
  - Ground truth
- Aims at Validation
  - Establish profile
  - Determine level of performance to qualify (for test sites)
    - Define performance metrics
    - Establish baseline to reach
- Software tools not primary aim (Uri Shreter)
  - Scanning parameters are more important
  - Scanning and analysis data needs to identify volumetric changes
  - Combination of scanning and software needed
  - Metrics needed
  - Accuracy measurements
- 2 Components (Nicholas Petrick)
  - What performance level is required
  - Structure of evaluation needed
    - Use data we already have
- Idea of “acceptable” performance is a moving target (Charles Fenimore)
  - Publishable results
    - Best algorithms
  - Visible incentives of products
  - Action driven by available data
- Agreement of what we want (Andrew Buckler)
  - Replace “software tools” with “those sources of variability” from the matrix
  - Replace “complete for best-in-class” with “vendors,” not specific to software developers
- Where does/can QIBA fit this process?
  - QIBA to establish the requirement; IHE in only a process to be studied
• Is another meeting between QIBA Tech Committee Chairs and IHE players needed?
  o Another iteration of the IHE process?
  o Chris Carr (RSNA) (Steering Committee)
  o Nikolaus Wirsz to speak to Gudrun Zahlmann to determine issues
  o QIBA Steering/Planning Committee call scheduled this week

• Possible Goals (Uri Shreter)
  o Short term
    ▪ Validation methods
  o Long term
    ▪ Incorporation into standards

• Requirements (Andrew Bucker)
  o Integration requirements
    ▪ DICOM headers
  o Performance requirements
    ▪ Level of resolution

• No clear time-frame established (Daniel Sullivan)
  o Dependant on people in group to decide
  o Roadmap and issues
  o Clinical endpoint
  o Huge interest with pharmaceutical industry
    ▪ Tumor trials

• Timelines would be helpful (Daniel Nicolson)
  o Dates/action items for software testing
  o Common plan with goals
  o List tasks

• Availability of data-sets is the biggest issue/risk (Rick Avila)
  o Data gathering will take time
  o Available data not “good enough”
  o Clinical data needed
  o Incomplete RECIST markup with RIDER data
    ▪ Diagnostic accuracy issues

• Pharma requirement (P. David Mozley)
  o RIDER to supply two data-sets
  o Consortium needed for pharmaceutical industry
  o Vendors to develop software based on these two data-sets
  o This group to select data-sets

• Still needed
  o Protocol/plan to carryout phantom studies
  o Anthropomorphic phantom
  o Current RIDER data collection

Substitute host required for July 21, 2008 WebEx